443 related articles for article (PubMed ID: 14512874)
21. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
22. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
[TBL] [Abstract][Full Text] [Related]
23. Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture.
Cheney IW; Naim S; Lai VC; Dempsey S; Bellows D; Walker MP; Shim JH; Horscroft N; Hong Z; Zhong W
Virology; 2002 Jun; 297(2):298-306. PubMed ID: 12083828
[TBL] [Abstract][Full Text] [Related]
24. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
[TBL] [Abstract][Full Text] [Related]
25. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
27. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
[TBL] [Abstract][Full Text] [Related]
28. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
29. Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro.
Kuga C; Enomoto H; Aizawa N; Takashima T; Ikeda N; Ishii A; Sakai Y; Iwata Y; Tanaka H; Saito M; Iijma H; Nishiguchi S
Biochem Biophys Res Commun; 2014 Nov; 454(3):453-8. PubMed ID: 25450683
[TBL] [Abstract][Full Text] [Related]
30. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.
Contreras AM; Hiasa Y; He W; Terella A; Schmidt EV; Chung RT
J Virol; 2002 Sep; 76(17):8505-17. PubMed ID: 12163570
[TBL] [Abstract][Full Text] [Related]
31. Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.
Satoh S; Mori K; Ueda Y; Sejima H; Dansako H; Ikeda M; Kato N
PLoS One; 2015; 10(2):e0118313. PubMed ID: 25699517
[TBL] [Abstract][Full Text] [Related]
32. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
33. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
[TBL] [Abstract][Full Text] [Related]
34. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent.
Mejer N; Galli A; Ramirez S; Fahnøe U; Benfield T; Bukh J
Virology; 2020 Jan; 540():132-140. PubMed ID: 31778898
[TBL] [Abstract][Full Text] [Related]
35. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
[TBL] [Abstract][Full Text] [Related]
36. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
37. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.
Chen M; Xu Y; Li N; Yin P; Zhou Q; Feng S; Wu T; Wei L; Wang H; Fu Y; Li YP
J Gen Virol; 2021 Dec; 102(12):. PubMed ID: 34949310
[TBL] [Abstract][Full Text] [Related]
38. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
[TBL] [Abstract][Full Text] [Related]
39. Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome.
Trejo-Avila L; Elizondo-González R; Trujillo-Murillo Kdel C; Zapata-Benavides P; Rodríguez-Padilla C; Rivas-Estilla AM
Ann Hepatol; 2007; 6(3):174-80. PubMed ID: 17786145
[TBL] [Abstract][Full Text] [Related]
40. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
Bassit L; Grier J; Bennett M; Schinazi RF
Antivir Chem Chemother; 2008; 19(1):25-31. PubMed ID: 18610555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
